Orphazyme A/S
Company announcement
No. 02/2022
www.orphazyme.com
Company Registration No. 32266355
Copenhagen,
Tuesday, February 15, 2022 at
at the Company’s address Ole Maaløes Vej 3, DK-2200 Copenhagen N,
In order to continuously provide the Company with the necessary flexibility to raise new capital to continue funding of its operations and protract a long-term capital structure, the Board of Directors proposes a number of authorizations to be approved by the Extraordinary General Meeting, including authorizations to issue shares, convertible bonds and warrants.
In general, the Board of Directors believes that the proposed authorizations will benefit the Company and its shareholders as they would provide flexibility to raise additional capital to fund the Company’s product candidate, arimoclomol, for the treatment of NPC during the US and EU regulatory approval processes.
Covid-19
We expect the current Covid-19 health risks and government precautions to continue on the date of the Extraordinary General Meeting.
Shareholders wishing to attend the Extraordinary General Meeting in person are encouraged not to bring advisors or other authorized guests to limit the number of physical attendees at the Extraordinary General Meeting. Further, meeting participants will be asked to present a valid corona passport and meeting participants having or showing symptoms of virus infection are kindly requested not to attend the meeting.
Shareholders who do not attend the Extraordinary General Meeting are encouraged to vote by submitting a postal vote or a proxy to the Board of Directors, as described below. Shareholders may submit written questions to the Company’s management before the Extraordinary General Meeting.
The above precautions are based on rules and recommendations issued by the Danish Health Authorities effective on the date hereof. If applicable rules and recommendations are updated before the Extraordinary General Meeting, additional precautions may be taken.
The notice to convene the Extraordinary General Meeting is attached as well as Appendix 1: Candidate for the Board of Directors.
Additional information about the Extraordinary General Meeting is available on the Company’s website: https://orphazyme.gcs-web.com/annual-general-meeting-0
For additional information, please contact
About
About arimoclomol
Arimoclomol is an investigational drug candidate that amplifies the production of heat shock proteins (HSPs). HSPs can rescue defective misfolded proteins, clear protein aggregates, and improve the function of lysosomes. Arimoclomol is administered orally, and has now been studied in 10 Phase 1, four Phase 2, and three pivotal Phase 2/3 trials. Arimoclomol has received Orphan Drug Designation (ODD) for NPC in the US and EU. Arimoclomol has received Fast-Track Designation (FTD), Breakthrough Therapy Designation (BTD), and Rare Pediatric Disease Designation (RPDD) from the
Forward-looking statement
This company announcement may contain certain forward-looking statements under the
Attachments
- 02-2022 Notice to convene Extraordinary General Meeting
- Notice to convene Extraordinary General Meeting 2022
- Appendix 1 - Candidate for the Board of Directors
© OMX, source